

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/13	A1	(11) International Publication Number: WO 93/09769 (43) International Publication Date: 27 May 1993 (27.05.93)
(21) International Application Number: PCT/US92/00888 (22) International Filing Date: 5 February 1992 (05.02.92) (30) Priority data: 793,036 15 November 1991 (15.11.91) US (71) Applicant: SEPRACOR, INC. [US/US]; 33 Locke Drive, Marlborough, MA 01752 (US). (72) Inventors: YOUNG, James, W. ; 295 Still River Road, Still River, MA 01467 (US). BARBERICH, Timothy, J. ; 71 Nashoba Road, Concord, MA 01742 (US). (74) Agents: MISROCK, S., Leslie et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE (57) Abstract Methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of unwanted, adverse toxic or psychological effects. In addition, methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is useful in treating migraine headaches, pain, in particular chronic pain, and obsessive-compulsive disorders. Further, methods and compositions for treating a condition alleviated or improved by inhibition of serotonin uptake in serotonergic neurons and platelets in a human using optically pure S(+) fluoxetine are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	MI	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE

This is a continuation-in-part of copending
5 application Serial No. 07/566,655, filed August 13,
1990 which is incorporated by reference here in its
entirety.

1. BACKGROUND OF THE INVENTION

10 This invention relates to a novel
composition of matter which possesses potent
antidepressant activity as a serotonin uptake
inhibitor while avoiding the usual detrimental
factors, unwanted effects and adverse toxic or
15 psychological effects associated with such agents.
Also disclosed are methods of using said composition
to treat depression while avoiding the usual
detrimental factors, unwanted effects and side effects
associated with such agents.

20 The invention further relates to a novel
composition of matter containing optically pure S(+)
fluoxetine which has activity as a weight loss agent
while avoiding the usual detrimental factors, unwanted
effects, and adverse toxic or psychological effects
25 which are associated with the racemic mixture of
fluoxetine. In addition, these compositions possess
potent activity in the treatment of migraine
headaches, pain, and obsessive-compulsive disorders,
while avoiding the usual detrimental factors, unwanted
30 effects and adverse toxic or psychological effects
associated with the racemic mixture of fluoxetine.
Also disclosed are methods of using these novel
compositions of matter to treat migraine headaches,
35 pain, obsessive-compulsive disorders and obesity or
weight gain in a human by administering pure S(+)

fluoxetine. These methods also avoid the usual detrimental factors, unwanted effects, and adverse toxic or psychological effects associated with administration of the racemic mixture of fluoxetine.

5 The active compound of this composition and method is an optical isomer of the compound fluoxetine which is described in U.S. Patent Nos. 4,018,895 and 4,194,009 to Molloy, et al. Chemically, this isomer is (+)N-methyl-3-phenyl-3-[(α,α,α -trifluoro-p-tolyl)-oxy]-propylamine, herein after referred to as S(+)
10 fluoxetine.

Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an
15 optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes (+) and (-) or \underline{d} and \underline{l} are employed to designate the sign of rotation of plane-polarized light by the
20 compound, with (-) or \underline{l} meaning that the compound is levorotatory. A compound prefixed with (+) or \underline{d} is dextrorotatory. For a given chemical structure, these compounds, called stereoisomers, are identical except that they are mirror images of one another. A
25 specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric or racemic mixture.

Stereochemical purity is of importance in the field of pharmaceuticals, where 12 of the 20 most
30 prescribed drugs exhibit chirality. A case in point is provided by the L-form of propranolol, which is known to be 100 times more potent than the D-enantiomer.

Furthermore, optical purity is important
35 since certain isomers may actually be deleterious

rather than simply inert. For example, the D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy. However, its L-thalidomide
5 counterpart was discovered to be a potent teratogen.

Fluoxetine (Prozac®), which is the subject of the present invention, is available only as a racemic mixture. That is, it is a mixture of optical isomers, called enantiomers.

10 The racemic mixture of fluoxetine, in addition to its use as an antidepressant, has a wide spectrum of actual and potential activities which include:

- Treatment of diabetes (EPA 88303930.7)
- 15 - Assisting in weight loss - i.e.,
appetite suppression (U.S. Patent No. 4,895,845)
- Treatment of alcohol abuse (U.S. Patent No. 4,777,173)
- 20 - Analgesia - control of pain (U.S. Patent Nos. 4,698,342 and 4,594,358)
- Treatment of atherosclerosis (U.S. Patent No. 4,444,778)
- Improvement of memory (U.S. Patent No. 25 4,647,591)
- Treatment of anxiety (U.S. Patent No. 4,590,213)
- Treatment of hypertension (U.S. Patent No. 4,329,356)
- 30 - Treatment of Huntington's chorea and schizophrenia (Scrip's New Product Review No.7, "Fluoxetine", PJB Publications Ltd. 1986)

35 Whereas the foregoing Molloy et al. patents, in addition to the above discussed European patent

application and U.S. patents, recognize that compounds such as fluoxetine have optically active forms, no example of an optically active form is given. Furthermore, prior art studies with the enantiomers of fluoxetine have generally concluded that the
5 fluoxetine enantiomers are equipotent and that there is no advantage in the use of the pure S-enantiomer. See, Robertson et al., J. Med. Chem., 31: 1412-1417 (1988). However, it has now been discovered that
10 there are indeed unforeseen advantages in the use of the pure S-enantiomer of fluoxetine.

Various researchers have presented a limited amount of pharmacological data on the enantiomers of fluoxetine. See, Fuller et al., Pharm. Biochem.
15 Behav., Vol. 24 pg. 281-284 (1986); Robertson et al., J. Med. Chem., Vol. 31 pg. 1412-1417 (1988); Wong et al. Drug Devel. Res. Vol. 6 pg. 397-403 (1985); Wong et al., Pharm. Biochem. Behav., Vol. 31 pg. 475-479 (1988). These references are limited by their failure
20 to provide complete dose-response or pharmacokinetic analyses, resulting only in qualitative impressions on certain matters.

The primary use of fluoxetine is in the treatment of depression, which along with mania falls
25 under the heading of affective disorders. Mania and depression are characterized by changes in mood as the primary symptom. Either of these two extremes of mood may be accompanied by psychosis with disordered thought and delusional perceptions. Psychosis may
30 have, as a secondary symptom, a change in mood, and it is this overlap with depression that causes much confusion in diagnosis. Severe mood changes without psychosis frequently occur in depression and are often accompanied by anxiety. Depression is characterized
35 by feelings of intense sadness or pessimistic worry,

agitation, self-deprecation, physical changes (including insomnia, anorexia, and loss of drive, enthusiasm, and libido), and mental slowing. Among the more common treatments for depression are the
5 administration of a tricyclic antidepressant agent.

Fluoxetine is not in the class of drugs known as tricyclic antidepressants. Its antidepressant action is presumed to be based on its highly specific inhibition of serotonin uptake in
10 serotonergic neurons and platelets in the brain. It is also chemically unrelated to tetracyclic or other available antidepressant agents.

Fluoxetine can also be used to assist in weight loss as disclosed in U.S. Patent No. 4,895,845
15 to Seed. The causes of excess body weight and/or obesity are complex; however, a common denominator in the overweight person's diet is a caloric intake which exceeds that person's body expenditures. One method of treating a person who is overweight and/or obese is
20 to restrict that person's caloric intake, in combination with an exercise regimen. This method may be limited in its effectiveness since many overweight or obese people have developed eating and activity patterns which are counterproductive to achieving
25 weight reduction. Another method to treat overweight or obese patients is to administer appetite suppressant drugs in conjunction with a weight reduction program. The drawback to this method is that many appetite suppressant drugs produce unwanted
30 or adverse effects which limit their usefulness such as long duration of action which results in severe appetite suppression.

It has also been suggested that fluoxetine could be used to treat migraine headaches which are a
35 paroxysmal disorder characterized by recurrent attacks

of said headaches, with or without associated visual and gastrointestinal disturbances. The cause is unknown, but evidence suggests a genetically transmitted functional disturbance of cranial circulation. Prodromal symptoms may be due to intracerebral vasoconstriction, and the head pain to dilation of scalp arteries. Migraine may occur at age but usually begins between ages 10 and 30, more often in women than in men. Migraine headaches may be preceded by a short period of depression, irritability, restlessness or anorexia, and in some patients by scintillating scotomas, visual field defects, paresthesias, or (rarely) hemiparesis. These symptoms may disappear shortly before the headache appears or may merge with it. Pain is either unilateral or generalized. Symptoms usually follow a pattern in each patient, except that unilateral headaches may not always be on the same side. The patient may have attacks daily or only once in several months.

Furthermore, it has also been suggested that fluoxetine could be used to treat pain, in particular chronic pain. Pain is a complex subjective phenomenon comprised of a sensation indicating real or potential tissue damage and the affective response this generates. Pain can be classified as either acute or chronic pain. Acute pain is an essential biologic signal of the potential for or the extent of injury. It is usually short-lived and is associated with hyperactivity of the sympathetic nervous system; e.g., tachycardia, increased respiratory rate and blood pressure, diaphoresis, and pupillary dilation. The concurrent affect is anxiety. Treatment involves removal of the underlying etiology if possible and the use of analgesic drugs. Chronic pain is defined as

pain persisting for greater than six months. Pain of this duration loses its adaptive biologic role.

Vegetative signs gradually develop; e.g., lassitude, sleep disturbance, decreased appetite, loss of taste
5 for food, weight loss, diminished libido, and constipation. A depressed affect predominates. In many patients, organic disease may be insufficient to explain the degree of pain or may be altogether absent. In these patients, as well as in many with
10 organic disease, the psychologic factors become the primary contributor to impairment. Therapy is often difficult and prognosis is guarded.

In addition, it has been postulated that fluoxetine is effective in the treatment of obsessive-
15 compulsive disorders. This is a neurotic disorder characterized by the presence of recurrent ideas and fantasies (obsessions) and repetitive impulses or actions (compulsions) that the patient recognizes as morbid and toward which he feels a strong inner
20 resistance. Anxiety is a central feature, but in contrast to the phobias (where the patient is anxious in the face of external dangers of which he perceives himself to be the passive victim), the anxiety arises in response to internally derived thoughts and urges
25 that the patient fears he may actively carry out despite his wishes not to. Obsessive-compulsive patients comprise less than 5% of those with neurotic disorders, and about 0.05% of the population at large. The neurosis affects men and women equally and tends
30 to be found in individuals from upper socioeconomic levels and with higher intelligence.

Fluoxetine has been shown to have certain advantages over other antidepressant drugs. Antagonism of muscarinic, histaminergic and α_1
35 adrenergic receptors has been hypothesized to be

associated with various anticholinergic and cardiovascular effects of classical tricyclic antidepressant drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less
5 potently than do these tricyclic antidepressants. Thus, fluoxetine gives less anticholinergic side effects such as blurred vision, dry mouth, constipation and urinary retention. There is also less lowering of blood pressure, tachycardia and
10 arrhythmias.

While fluoxetine has certain advantages, it also has disadvantages. Among these disadvantages are side effects which include unwanted effects and adverse toxic or psychological effects. The most
15 frequently reported side effects associated with racemic fluoxetine are headaches, nervousness, anxiety and insomnia. These are reported by 10% to 15% of patients treated with fluoxetine. These symptoms led to drug discontinuation in 5% of the patients treated
20 with the drug. It is also known that in some patients, use of fluoxetine is associated with severe anxiety leading to intense violent suicidal thoughts and self mutilation. Teicher et al., Am. J. Psychiatry, 147(2): 207-210 (1990). In other patients
25 manic behavior follows treatment with fluoxetine. Other side effects associated with fluoxetine include nausea, nervousness, tremor, fatigue, mouth dryness, dyspepsia, constipation, excessive sweating, upper respiratory infection, flu-like syndrome, diarrhea and
30 drowsiness.

Another disadvantage of racemic fluoxetine is its long half-life and the concomitant delay in onset of action. The half-life of racemic fluoxetine is approximately 2 to 3 days. Steady state plasma
35

concentrations are achieved only after continuous dosing for weeks.

A further disadvantage of racemic fluoxetine is that it has a low response rate. Overall, 44% of the patients being treated with fluoxetine showed antidepressant effect. In patients who had not previously responded to other antidepressant therapy the response to fluoxetine was 43%. In addition, in patients with no previous treatment with antidepressants, or with a history of good response to previous treatment, response to fluoxetine was 56%. (*Scrip's New Product Review*, "No. 7 Fluoxetine", pages 13-14, 1986).

Another disadvantage of racemic fluoxetine is that in addition to its use as an antidepressant it has activities such as severe appetite suppression, drowsiness, analgesia and hypotension. These other activities may be unwanted effects when treating a patient suffering from depression or even when treating obesity or weight gain, *i.e.*, where only moderate appetite suppression of short duration is desired.

It is therefore desirable to find a compound with the advantages of fluoxetine which would not have the above described disadvantages.

2. SUMMARY OF THE INVENTION

It has now been discovered that the S(+) isomer of fluoxetine does not have certain side effects, including causing nervousness, anxiety, insomnia, and adverse psychological effects; has a fast onset of action and an increased response rate. It has also been discovered that with the use of the S(+) isomer of fluoxetine it is possible to avoid other activities of the racemic compound which would

be unwanted effects when treating a patient suffering from depression. Thus, the S(+) isomer of fluoxetine is useful for methods of treating depression and in the compositions used thereof where these detrimental effects will be avoided.

It has also been discovered that with the use of the S(+) isomer of fluoxetine it is possible to achieve weight reduction or weight loss through moderate appetite suppression while avoiding unwanted effects, such as severe appetite suppression, and adverse toxic or psychological effects associated with administration of the racemic mixture of fluoxetine. Also, the methods and compositions of the present invention utilizing optically pure S(+) fluoxetine provide an increased response rate.

In addition, it has been discovered that the S(+) isomer of fluoxetine is useful in the treatment of migraine headaches, the treatment of pain, in particular chronic pain, and in the treatment of obsessive-compulsive disorders. The unwanted effects and adverse toxic or psychological effects which are avoided or decreased by administering the S(+) isomer of fluoxetine include but are not limited to headaches, nervousness, anxiety, nausea, diarrhea, anorexia, insomnia, severe appetite suppression, inner restlessness (akathisia) suicidal thoughts and self mutilation.

Novel compositions of matter containing optically pure S(+) fluoxetine which have appetite suppressant activity while avoiding the above described unwanted effects and adverse toxic or psychological effects associated with the racemic mixture of fluoxetine are also disclosed.

Further included within the present invention are novel compositions of matter containing

optically pure S(+) fluoxetine which are useful in the treatment of migraine headaches, the treatment of pain, in particular chronic pain, and the treatment of obsessive-compulsive disorders. These novel

5 compositions also avoid the above-described unwanted, adverse toxic or psychological effects associated with the racemic mixture of fluoxetine.

3. DETAILED DESCRIPTION OF THE INVENTION

10 The present invention encompasses a method of eliciting an antidepressant effect while avoiding the concomitant liability of adverse toxic or psychological effects, delayed onset of action or low response rate associated with the racemic mixture
15 which comprises administering to a patient in need of antidepressant therapy an amount sufficient to alleviate human depression, but insufficient to cause said adverse toxic or psychological effects, delayed onset of action and low response rate, of S(+)
20 fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer.

The present invention also encompasses a method of treating obesity or weight gain in a human while avoiding unwanted effects, adverse toxic or
25 psychological effects or low response rate associated with the racemic mixture of fluoxetine, comprising administering to a human in need of treatment of obesity or weight gain an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof,
30 substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate said human's obesity or weight gain but insufficient to cause said unwanted effects and adverse toxic or psychological effects associated with administration of racemic
35 fluoxetine.

In addition, the present invention encompasses a method of treating migraine headaches, pain or obsessive-compulsive disorders while avoiding concomitant liability of unwanted effects, adverse
5 toxic or psychological effects or low response rate associated with the racemic mixture of fluoxetine, comprising administering to a patient in need of treatment of migraine headaches, treatment of pain
10 treatment of obsessive-compulsive disorders, an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to treat the patient's migraine headache, pain or obsessive-compulsive disorders but insufficient to cause said
15 unwanted effects, adverse toxic or psychological effects or low response rate associated with administration of racemic fluoxetine.

The present invention further encompasses a method of eliciting an antidepressant effect while
20 avoiding unwanted effects, which comprises administering to a patient in need of antidepressant therapy an amount sufficient to alleviate a human's depression, but insufficient to cause said unwanted effects of S(+) fluoxetine or a pharmaceutically
25 acceptable salt thereof, substantially free of its R(-) stereoisomer.

The present invention also encompasses an antidepressant composition for the treatment of a patient in need of antidepressant therapy which
30 comprises an amount sufficient to alleviate the depression but insufficient to cause adverse toxic or psychological effects, delayed onset of action and low response rate of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its
35 R(-) stereoisomer.

Also embodied in the present invention is an antidepressant composition adapted for the treatment of a patient in need of antidepressant therapy which comprises an amount sufficient to alleviate the depression but insufficient to cause the unwanted effects of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer.

Further, embodied in the present invention is a composition that is useful for treating obesity or weight gain in a human comprising an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to achieve weight loss or prevent weight gain while avoiding unwanted effects, adverse toxic or psychological effects or low response rate associated with the racemic mixture of fluoxetine.

In addition, the present invention encompasses compositions that are adapted for treating migraine headaches, pain, or obsessive-compulsive disorders, comprising an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate the above-described afflictions, but insufficient to cause unwanted effects, adverse toxic or psychological effects or low response rate of racemic fluoxetine.

Furthermore, pure S(+) fluoxetine is also more effective for the treatment of migraine headaches, the treatment of pain, in particular chronic pain, and to treat obsessive-compulsive disorders, since as previously discussed the racemic mixture of fluoxetine has a delayed onset of action, and has a low response rate whereas S(+) isomer of

fluoxetine does not cause unwanted effects or adverse
toxic or psychological effects and it has a high
response rate. Thus, it is more desirable to use the
S(+) isomer of fluoxetine. With regard to migraine
5 headaches in particular, the reductions of adverse
toxic or psychological effects by the S(+) isomer
fluoxetine allows for treatment of the symptoms on
acute basis and also prophylactically, without the
previously described adverse effects or complicati

10 In addition, the present invention
encompasses a method for treating a condition
alleviated or improved by inhibition of serotonin
uptake in serotonergic neurons and platelets in a
human while avoiding unwanted, adverse toxic or
15 psychological effects associated with the racemic
mixture of fluoxetine which comprises administering
a human in need of such therapy an amount of S(+)
fluoxetine or a pharmaceutically acceptable salt
thereof, substantially free of its R(-) stereoisomer:
20 said amount being sufficient to alleviate said
condition but insufficient to cause said adverse
effects. Conditions that may be alleviated or
improved by inhibition of serotonin uptake in
serotonergic neurons and platelets include but are
25 limited to alcohol abuse, anxiety, memory disorders
Huntington's chorea and schizophrenia.

Further encompassed in the present invention
is a composition for the treatment of a condition
alleviated or improved by inhibition of serotonin
30 uptake in serotonergic neurons and platelets in a
human which comprises an amount of S(+) fluoxetine or
a pharmaceutically acceptable salt thereof,
substantially free of its R(-) stereoisomer, said
amount being sufficient to alleviate said condition
35 but insufficient to cause unwanted, adverse toxic or

psychological effects associated with the administration of racemic fluoxetine.

The racemic mixture of fluoxetine (i.e., a mixture of R and S stereoisomers) has antidepressant effect; however this racemic mixture causes adverse toxic or psychological effects, has a delayed onset of action, and has a low response rate. The S(+) isomer of fluoxetine does not cause these adverse toxic or psychological effects, has a rapid onset of action and has a high response rate. Thus, it is much more desirable to use the S(+) isomer of fluoxetine.

Furthermore, although there is some variability from one patient to another, it is generally observed that, by administering an effective amount of only the S(+) isomer of fluoxetine it is possible to accomplish a more "targeted" therapy. A more "targeted" therapy means that by using the S(+) isomer of fluoxetine the compound's broad activity can be taken advantage of without also having unwanted effects. This is important since it is not desirable for all patients to be administered a compound with such a complex and multifaceted spectrum of activity. The term "unwanted effects" includes but is not limited to (1) severe appetite suppression; (2) drowsiness or analgesia; and (3) hypotension. Thus, by administering to a patient the S(+) isomer of fluoxetine, significant antidepressant activity is obtained without the above-identified unwanted effects which are associated with the racemic mixture of fluoxetine.

The term "adverse toxic or psychological effects" includes but is not limited to headaches, nervousness, anxiety, insomnia, nausea, diarrhea, drowsiness, mouth dryness, tremor, anorexia, dyspepsia, excessive sweating, upper respiratory

infection, flu-like syndrome, intense violent suicidal thoughts and manic behavior.

The term "side effect" as used herein means effects which are undesirable or which act against the intended beneficial effect of the compositions. The
5 term "side effect" encompasses adverse toxic or adverse psychological effects.

The term "substantially free of the R(-) stereoisomer" as used herein means that the
10 composition contains a greater proportion of the S(isomer of fluoxetine in relation to the R(-) isomer fluoxetine. In a preferred embodiment the term "substantially free of its R(-) isomer" as used here means that the composition contains at least 90% by
15 weight of S(+) fluoxetine and 10% by weight or less R(-) fluoxetine, these percentages being based on the total amount of fluoxetine present. In the most preferred embodiment the term "substantially free of the R(-) stereoisomer" means that the composition
20 contains at least 99% by weight S(+) fluoxetine and or less of R(-) fluoxetine. In another preferred embodiment, the term "substantially free of its R(-) stereoisomer" as used herein means that the composition contains 100% by weight of S(+)
25 fluoxetine. Again, the above percentages are based on the total amount of fluoxetine present. The terms "substantially optically pure S(+) fluoxetine" and "optically pure S(+) isomer of fluoxetine" are also encompassed by the above-described amounts.

30 The term "eliciting an antidepressant effect" means relief from the symptoms associated with depression, which include but are not limited to feelings of intense sadness or pessimistic worry, agitation, self-deprecation, physical changes
35

(including insomnia, anorexia, and loss of drive enthusiasm and libido) and mental slowing.

The term a "method of treating migraine headaches, pain or obsessive-compulsive disorders" as
5 used herein means relief from the symptoms and/or effects associated with these disorders that are described above.

The term a "method of treating obesity or weight gain" as used herein means a method of non-
10 severely suppressing the appetite of a human for a short time such that food consumption is reduced by the non-severe appetite suppression.

The term a "method for treating a condition alleviated or improved by inhibition of serotonin
15 uptake in serotonergic neurons and platelets" as used herein means relief from the symptoms and/or effects associated with these disorders.


The synthesis of the S(+) isomer of fluoxetine can be performed by two methods which are
20 as follows:

Method 1

This method is disclosed in Gao, et al. J. Org. Chem. Vol. 53, No. 17, pp. 4081-4084 (1988). It involves the use of 1-phenyl-1,3-propanediols, which
25 are key intermediates. The 1-phenyl-1,3-propanediols are prepared from cinnamyl epoxy alcohols by Red-Al[®] reduction. The chiral cinnamyl epoxy alcohols are made by asymmetric epoxidation of cinnamyl alcohols as disclosed in Gao, et al.

30 (S)-(+)-fluoxetine hydrochloride is prepared from (2R,3R)-epoxycinnamyl alcohol obtained by the asymmetric epoxidation disclosed in Gao et al. utilizing (-)-DIPT.

The reaction scheme is as follows:



(R)-(-)-fluoxetine hydrochloride is prepared from (2S,3S)-epoxycinnamyl alcohol obtained by the asymmetric epoxidation disclosed in Gao et al. utilizing (+)-DIPT.


5

Method 2

This method is based on the asymmetric reduction of ketone with a chiral borane reagent as disclosed in U.S. Patent No. 4,868,344 to H.C. Brown.

10

The reaction scheme is as follows:



The magnitude of a prophylactic or therapeutic dose of S(+) fluoxetine will, of course, vary with the nature and the severity of the condition to be treated and its route of administration. It
5 will also vary according to the age, weight and response of the individual patient. In general, the daily dose range for use as an anti-depressant will lie within the range of from about 1 mg to about 100 mg per day, preferably about 20 mg to about 80 mg per
10 day, and most preferably from about 40 mg to about 80 mg per day, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases. The terms encompassed by the above-described amounts include: "an amount
15 sufficient to alleviate said human's depression but insufficient to cause said adverse toxic or psychological effects, delayed onset of action or low response rate", "said amount being sufficient to alleviate migraine headaches, pain or an obsessive-
20 compulsive disorder but insufficient to cause unwanted, adverse toxic or psychological effects", "said amount being sufficient to alleviate said human's obesity or weight gain but insufficient to cause said unwanted, adverse toxic or psychological
25 effects", "said amount being sufficient to achieve weight loss but insufficient to cause said unwanted, adverse toxic or psychological effects", "said amount being sufficient to alleviate said condition but insufficient to cause said unwanted, adverse toxic or
30 psychological effects" wherein said condition is alcohol abuse, anxiety, memory disorders, Huntington's chorea or schizophrenia.

Any suitable route of administration may be employed for providing the patient with an effective
35 dosage of S(+) fluoxetine. For example, oral, rectal,

parenteral, transdermal, subcutaneous, intramuscular, inhalation and the like may be employed. Dosage forms include tablets, trochees, dispersions, suspensions, solutions, capsules, patches and the like.

5 The pharmaceutical compositions of the present invention comprise S(+) fluoxetine as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic
10 ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic acids and organic acids.

 Since the compound of the present invention
15 is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzene-sulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic,
20 hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like. Particularly preferred are hydrobromic, hydrochloric,
25 phosphoric and sulfuric acids.

 The compositions include compositions suitable for oral, rectal, and parenteral (including subcutaneous, intramuscular, and intravenous)
30 administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated. The most preferred route of administration in the present invention is oral. The compositions may be inconveniently
35 presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

In the case where an oral composition is employed, a suitable dosage range for use is, e.g., from about 1 mg to about 100 mg of fluoxetine per day, preferably from about 20 mg to about 80 mg per day and
5 most preferably from about 40 mg to about 80 mg per day.

In practical use, S(+) fluoxetine can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to
10 conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any
15 of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions;
20 or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral
25 preparations being preferred over the liquid preparations. The most preferred solid oral preparation is capsules. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case
30 solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out above, the compound of the present invention may
35 also be administered by controlled release means

and/or delivery devices such as those described in U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200 and 4,008,719, the disclosures of which are hereby incorporated herein by reference.

5 The use of a racemic mixture of fluoxetine in a sustained release formulation is disclosed and/or claimed in U.S. Patent Nos. 4,797,286 and 4,847,092.

Pharmaceutical compositions of the present invention suitable for oral administration may be
10 presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-
15 in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In
20 general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may
25 be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder,
30 lubricant, inert diluent, and/or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 5
35 mg to about 100 mg of the active ingredient and each

cachet or capsule contains from about 5 to about 100 mg of the active ingredient. Most preferably the tablet, cachet or capsule contains 20 mg of active ingredient.

5 The invention is further defined by reference to the following examples describing in detail the preparation of the compound and compositions of the present invention. It will be apparent to those skilled in the art that many
10 modifications, both to materials and methods, may be practiced without departing from the purpose and interest of this invention.

All temperatures are in degrees Celsius.

15 4. EXAMPLES

4.1 EXAMPLE 1

Synthesis of R(-) and S(+) Fluoxetine

Reduction of epoxycinnamyl alcohols with Red-Al;
synthesis of fluoxetine

20 Part 1

(R)-3-Phenyl-1,3-dihydroxypropane

25

30

35




To a solution of (-)-(2S,3S)-epoxycinnamyl alcohol (1) (1.5 g, 10.0 mmol) (synthesized by the method disclosed in Gao et al., J. Org. Chem., Vol. 53, No. 17, pp. 4081-4084 (1988.), in dimethoxyethane 5 (50 mL) was added a 3.4 molar solution of Red-Al® in toluene (3.1 mL, 10.5 mmol) dropwise under nitrogen at 0°C. After stirring at room temperature for three hours, the solution was diluted with ether and quenched with 5% HCl solution. After stirring at room 10 temperature for 30 min, the resulting white precipitate formed was filtered and boiled with ethyl acetate and filtered again. The combined organic solutions were dried with magnesium sulfate. Concentration gave (R)-3-phenyl-1,3-dihydroxypropane 15 (2) as a slightly yellow oil which was used without further purification (1.5 g, 98%): ¹H NMR (CDCl₃) δ 7.2-7.3 (m, 5 H), 4.88-4.98 (m, 1 H), 3.78-3.86 (t, J = 7.5 Hz, 2), 3.3-3.4 (br. s, 1 H), 2.85-2.95 (br. s, 1 H), 1.84-2.08 (m, 2 H); the ratio of 1,3-diol to 20 1,2-diol was 20:1 by ¹H NMR analysis of the derived diacetate.

(S)-3-Phenyl-1,3-dihydroxypropane was prepared according to the above procedure starting with 300 mg of (+)-epoxycinnamyl alcohol to provide 25 300 mg of (S)-3-phenyl-1,3-dihydroxypropane (1,3-diol:1,2-diol=21:1).

30

35

Part 2

(S)-3-phenyl-3-hydroxypropyl-1-methanesulfonate

To a solution of (S)-3-phenyl-1,3-
15 dihydroxypropane (3) (2.71 g, 17.8 mmol) and
triethylamine (2.60 g, 25.6 mmol) in ether (90 mL) was
added dropwise MsCl (1.45 mL, 18.7 mmol) under
nitrogen at -10°C. After stirring at -10°C to 0°C for
3 h, the mixture was poured into ice water (30 mL) and
20 washed with 20% H₂SO₄, saturated aqueous NaHCO₃, brine,
and dried over magnesium sulfate. The crude products
were purified by chromatography eluting with 45% ethyl
acetate in hexane to give the title compound (4) as an
oil (3.50 g, 85%): ¹H NMR (CDCl₃, δ 7.3-7.4 (m, 5 H),
25 4.85-4.91 (t, J = 7.7 Hz, 1 H), 4.42-4.52 (m, 1 H),
4.22-4.32 (m, 1 H), 3.0 (s, 3 H), 2.3 (s, 1 H), 2.1-
2.2 (q, J = 7.7 Hz, 2 H).

(R)-3-Phenyl-3-hydroxypropyl-1-
methanesulfonate was prepared from (R)-3-phenyl-1,3-
30 dihydroxypropane by the above procedure in 74% yield.

These two compounds were either stored at
0°C or used soon after preparation.

Part 3(S)-N-Methyl-3-phenyl-3-hydroxypropylamine

5



10

(5)


(6)

15

A solution of (S)-3-phenyl-3-hydroxypropyl-1-methanesulfonate (5) (690 mg, 3.0 mmol) and methylamine (10 mL, 40% in water) in THF (10 mL) was heated at 65°C for 3 h. After cooling, the solution was diluted with ether and washed with saturated aqueous sodium bicarbonate, brine, and dried with anhydrous potassium carbonate. Concentration to dryness provided the title compound (6) (476 mg, 96% yield). ¹H NMR (CDCl₃) δ 7.2-7.4 (m, 5 H), 4.94 (dd, J = 3.8, 7.2 Hz, 1 H), 3.4-3.9 (br. s, 1 H), 2.84-2.92 (m, 2 H), 2.45 (s, 3 H), 1.68-1.92 (m, 3 H).

Following a procedure identical to the above, 1.15 g (R)-3-phenyl-3-hydroxypropyl-1-methanesulfonate yielded 837 mg of (R)-N-methyl-3-phenyl-3-hydroxypropylamine.

35

Part 4(R)-Fluoxetine hydrochloride

15

To a solution of (R)-N-methyl-3-phenyl-3-hydroxy-propylamine (7) (1.23 g, 7.45 mmol) in dimethyl acetamide (7 mL) was added sodium hydride (215 mg, 8.95 mmol) with cooling. The mixture was heated at 90°C for 1.5 h, and an orange solution resulted. To this solution was then added 4-chlorobenzotrifluoride (3.23 g, 2.40 mL, 17.9 mmol), and the mixture was heated at 100-105°C for 2.5 h. After cooling and dilution with toluene, the mixture was washed with water, and the aqueous layer was separated and extracted with toluene. The combined toluene solutions were then washed with saturated aqueous sodium bicarbonate, brine, and dried over magnesium sulfate. Concentration provided (R)-fluoxetine as an orange oil (1.97 g, 86%). The oil was dissolved in ether and acidified with hydrogen chloride gas (pH = 3-4) to give a acidic ethereal solution (no precipitate formed). The solution was concentrated at room temperature to give a yellow solid which was washed with ether to remove most of

20

25

30

35

the orange color. The slightly yellow solid was then recrystallized from acetonitrile at -20°C . The solid was collected and washed with ether to provide (R)-fluoxetine hydrochloride (8) as a white powder (1.90 g, 75%): mp $140-142^{\circ}\text{C}$ (lit. mp $140-141.5^{\circ}\text{C}$; $[\alpha]^{23}_{\text{D}} -2.16^{\circ}$ (c 1.62, MeOH); (lit. $[\alpha]^{23}_{\text{D}} -1.97^{\circ}$ [c 1.00, MeOH])); $[\alpha]^{23}_{\text{D}} +7.08^{\circ}$ (c 1.30, H_2O); (lit. $[\alpha]^{23}_{\text{D}} +10.32^{\circ}$ [c 1.00, H_2O]); IR (KBr, CDCl_3 , 2950, 2640, 2450, 1620, 1595, 1520, 1360, 1250, 1180, 1170, 1130, 1114, 1070, 840 cm^{-1} ; ^1H NMR (CDCl_3) δ 9.72 (br, s, 2 H), 7.40-7.43 (d, $J = 8.7$ Hz, 2 H), 7.25-7.33 (m, 5 H), 6.88-6.92 (d, $J = 8.7$ Hz, 2 H), 5.45-5.50 (dd, $J = 4.6, 7.9$ Hz, 1 H), 3.12 (br, s, 2 H), 2.55-2.62 (br, s, 3 H), 2.42-2.52 (m, 2 H); Anal. Calcd. for $\text{C}_{17}\text{H}_{19}\text{ClF}_3\text{NO}$: C, 59.05; H, 5.54; N, 4.05; F, 16.48; Cl, 10.25. Found: C, 58.84; H, 5.55; N, 3.94; F, 16.28; Cl, 10.50.

(S)-Fluoxetine hydrochloride was prepared by the above procedure from (S)-N-methyl-3-phenyl-3-hydroxypropylamine: mp $140-142^{\circ}\text{C}$ (lit mp $135-137^{\circ}\text{C}$); $[\alpha]^{23}_{\text{D}} -7.12^{\circ}$ (c 1.53, H_2O); lit $[\alpha]^{23}_{\text{D}} -10.85^{\circ}$ [c 1.00, H_2O]); Anal. Calcd. for $\text{C}_{17}\text{H}_{19}\text{ClF}_3\text{NO}$: C, 59.05; H, 5.54; N, 4.05. Found: C, 59.19; H, 5.42; N, 3.89.

25

30

35

4.2 EXAMPLE 2
ORAL FORMULATION

Tablets:

5	Formula	Quantity per Tablet (mg.)	
		<u>A</u>	<u>B</u>
10	Active Ingredient (S(+)) Fluoxetine Hydrochloride)	10.00	20.00
	Lactose	62.75	52.75
	Corn Starch	3.0	3.0
	Water (per thousand Tablets)	30.0 ml	30.0 ml
	Corn Starch	18.75	18.75
15	Magnesium Stearate	<u>0.5</u>	<u>0.5</u>
		125.00	125.00

*The water evaporates during manufacture

- 20 Blend the active ingredient S(+) fluoxeti.
hydrochloride with the lactose until uniform. Blend
the smaller quantity of cornstarch with the water and
add the resulting corn starch paste, then mix until a
25 uniform wet mass is formed. Add the remaining corn
starch to the resulting wet mass and mix until uniform
granules are obtained. Screen the granules through a
suitable milling machine, using a 1/4 inch stainless
steel screen. Dry the milled granules in a suitable
30 drying oven until the desired moisture content is
obtained. Mill the dried granules through a suitable
milling machine using 1/4 mesh stainless steel screen.
Blend in the magnesium stearate and compress the
resulting mixture into tablets of desired shape,
35 thickness, hardness and disintegration.

4.3 EXAMPLE 3
ORAL FORMULATION

Capsules:

5		<u>Quantity per Capsule</u>	
	<u>Formula</u>	<u>(mg.)</u>	
		<u>A</u>	<u>B</u>
10	Active ingredient	10.00	20.00
	Lactose	65.75	55.75
	Corn Starch	18.75	18.75
	Magnesium Stearate	<u>0.50</u>	<u>0.50</u>
		125.00	125.00

15

Blend the active ingredient, S(+) fluoxetine hydrochloride, lactose and corn starch until uniform; then blend the magnesium stearate into the resulting powder. Encapsulate the mixture into suitable sized
20 two-piece hard gelatin capsules.

25

30

35

What is claimed is:

1. A method of eliciting an antidepressant effect while avoiding concomitant liability of adverse toxic or psychological effects, delayed onset of action or low response rate, which comprises administering to a patient in need of antidepressant therapy an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate human depression, but insufficient to cause said adverse toxic or psychological effects, delayed onset of action or low response rate associated with the administration of racemic fluoxetine.
2. The method of claim 1 wherein S(+) fluoxetine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.
3. The method of claim 1 wherein the amount administered is 1 mg to 100 mg per day.
4. The method according to claim 3 wherein the amount administered is 20 mg to 80 mg per day.
5. The method according to claim 1 wherein said amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight of the total amount of fluoxetine.
6. The method according to claim 1 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer is administered together with a pharmaceutically acceptable carrier.
7. A method according to claim 2 wherein S(+) fluoxetine is administered as a hydrochloride salt.

8. An antidepressant composition adapted for the treatment of a patient in need of antidepressant therapy which comprises an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate depression but insufficient to cause adverse toxic or psychological effects, delayed onset of action or low response rate associated with the administration of racemic fluoxetine.

9. A composition according to claim 8 wherein the amount is 1 mg to 20 mg.

10. A composition according to claim 9 wherein said composition is administered from one to four times a day.

11. A composition according to claim 9 wherein said composition is administered twice a day.

12. A composition according to claim 9 wherein said composition is administered once a day.

13. A composition according to claim 9 which comprises S(+) fluoxetine hydrochloride.

14. A composition according to claim 13 adapted for oral administration.

15. A composition according to claim 13 adapted for intravenous delivery.

16. A composition according to claim 13 adapted for transdermal delivery.

17. The composition according to claim 8 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer is administered together with a pharmaceutically acceptable carrier.

18. A method of eliciting an antidepressant effect while avoiding unwanted effects of racemic fluoxetine which comprises administering to a patient

in need of antidepressant therapy an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate human depression, but insufficient to cause said unwanted effects.

19. The method of claim 18 wherein S(+) fluoxetine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.

20. The method of claim 18 wherein said unwanted effects are severe appetite suppression, drowsiness, analgesia or hypotension.

21. The method of claim 19 wherein the amount administered is 1 mg to 100 mg per day.

22. The method according to claim 21 wherein the amount administered is 20 mg to 80 mg per day.

23. The method according to claim 18 wherein said amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight of the total amount of fluoxetine.

24. The method according to claim 18 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer is administered together with a pharmaceutically acceptable carrier.

25. A method according to claim 21 wherein S(+) fluoxetine is administered as a hydrochloride salt.

26. An antidepressant composition adapted for the treatment of a patient in need of antidepressant therapy which comprises an amount of S(+) fluoxetine or a pharmaceutically acceptable salt

thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate the depression but insufficient to cause unwanted effects of racemic fluoxetine.

5 27. A composition according to claim 26 wherein said unwanted effects are severe appetite suppression, drowsiness, analgesia or hypotension.

 28. A composition according to claim 26 wherein the amount is 1 mg to 20 mg.

10 29. A composition according to claim 28 wherein said composition is administered from one to four times a day.

 30. A composition according to claim 29 wherein said composition is administered twice a day.

15 31. A composition according to claim 30 wherein said composition is administered once a day.

 32. A composition according to claim 28 which comprises S(+) fluoxetine hydrochloride.

20 33. A composition according to claim 32 adapted for oral administration.

 34. A composition according to claim 32 adapted for intravenous delivery.

 35. A composition according to claim 32 adapted for transdermal delivery.

25 36. The composition according to claim 26 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer is administered together with a pharmaceutically acceptable carrier.

30 37. A method of treating migraine headaches, pain or obsessive-compulsive disorders in a human while avoiding unwanted, adverse toxic or psychological effects, comprising administering to a human in need of treatment of migraine headaches, pain
35 or obsessive-compulsive disorders an amount of S(+)

fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate said human's migraine headaches, pain or obsessive-compulsive disorder but insufficient to cause said unwanted, adverse toxic or psychological effects associated with administration of racemic fluoxetine.

38. The method of claim 37 wherein S(+) fluoxetine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.

39. The method of claim 37 wherein the amount administered is about 1 mg to about 100 mg per day.

40. The method according to claim 39 wherein the amount administered is about 20 mg to about 80 mg per day.

41. The method of claim 40 wherein the amount administered is from about 25 mg to about 75 mg.

42. The method of claim 37 wherein the amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, is greater than approximately 90% by weight of the total amount of fluoxetine.

43. The method according to claim 37 wherein the amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight of the total amount of fluoxetine.

44. The method according to claim 37 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

45. A method according to claim 40 wherein S(+) fluoxetine is administered as its hydrochloride salt.

46. A composition adapted for the treatment
5 of a human having migraine headaches, pain or an obsessive-compulsive disorder, said composition comprising an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said
10 amount being sufficient to alleviate migraine headaches, pain or an obsessive-compulsive disorder but insufficient to cause the unwanted, adverse toxic or psychological effects of racemic fluoxetine.

47. A composition according to claim 46
15 wherein the amount is about 1 mg to about 20 mg.

48. A composition according to claim 47 wherein said composition is administered from one to four times a day.

49. A composition according to claim 47
20 wherein said composition is administered twice a day.

50. A composition according to claim 47 wherein said composition is administered once a day.

51. A composition according to claim 47 which comprises R(-) fluoxetine in the form of its
25 hydrochloride salt.

52. A composition according to claim 51 adapted for oral administration.

53. A composition according to claim 51 adapted for intravenous delivery.

30 54. A composition according to claim 51 adapted for transdermal delivery.

55. A composition according to claim 51 adapted for use in a parenteral administration.

35 56. A composition according to claim 46 wherein the amount of S(+) fluoxetine or a

pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of fluoxetine.

57. A composition according to claim 46 wherein the amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight of the total amount of fluoxetine.

58. The composition according to claim 46 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

59. A method of treating obesity or weight gain in a human while avoiding unwanted, adverse toxic or psychological effects, comprising administering to a human in need of treatment of obesity or weight gain an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate said human's obesity or weight gain but insufficient to cause said unwanted, adverse toxic or psychological effects associated with administration of racemic fluoxetine.

60. The method of claim 59 wherein the amount administered is about 1 mg to about 100 mg per day.

61. The method according to claim 60 wherein the amount administered is about 20 mg to about 80 mg per day.

62. The method according to claim 59 wherein the amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of fluoxetine.

63. The method according to claim 59 wherein the amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight of the total amount
5 of fluoxetine.

64. The method according to claim 59 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, is administered together with a
10 pharmaceutically acceptable carrier.

65. The method according to claim 59 wherein S(+) fluoxetine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.

15 66. A method according to claim 59 wherein S(+) fluoxetine is administered as its hydrochloride salt.

67. A composition adapted for the treatment of obesity or weight gain in a human, said composition
20 comprising an amount of S(+) fluoxetine, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate obesity or weight gain but insufficient to cause the unwanted, adverse toxic or psychological effects of racemic fluoxetine.

25 68. A composition according to claim 67 wherein the amount is about 1 mg to about 20 mg.

69. A composition according to claim 68 wherein said composition is administered from one to four times a day.

30 70. A composition according to claim 69 wherein said composition is administered twice a day.

71. A composition according to claim 70 wherein said composition is administered once a day.

72. A composition according to claim 68 which comprises R(-) fluoxetine as a hydrochloride salt.

73. A composition according to claim 72 adapted for oral administration.

74. A composition according to claim 72 adapted for intravenous delivery.

75. A composition according to claim 72 adapted for transdermal delivery.

76. A composition according to claim 67 wherein S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, is administered together with a pharmaceutically acceptable carrier.

77. A method for treating a condition alleviated or improved by inhibition of serotonin uptake in serotonergic neurons and platelets in a human, while avoiding unwanted, adverse toxic or psychological effects associated with the racemic mixture of fluoxetine, comprising administering to a human in need of such therapy an amount of S(+) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its R(-) stereoisomer, said amount being sufficient to alleviate said condition but insufficient to cause said unwanted, adverse toxic or psychological effects.

78. The method according to claim 77 wherein said condition alleviated or improved by inhibition of serotonin uptake in serotonergic neurons and platelets is selected from the group consisting of alcohol abuse, anxiety, memory disorders, Huntington's chorea and schizophrenia.

79. The method of claim 77 wherein S(+) fluoxetine is administered by intravenous infusion, transdermal delivery, orally as a tablet or a capsule.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/00888

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): A61K 31/13		
U.S.CL.: 514/646		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.CL.	514/646	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁸		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Chemical Abstracts, Volume 112, "Enantioselective practical syntheses of R - and S- fluoxetine", Corey, E.J. et al 2163285 (1990). see whole document	8-17,26-36, 46-58,67-76 85-94
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
05 MAY 1992	26 JUN 1992	
International Searching Authority	Signature of Authorized Officer	
ISA/US	S. J. FRIEDMAN	